SillaJen
215600.KQ
1.67 USD
-0.10
-5.65%
s
Overview
Last close
1.67 usd
Market cap
229.43M usd
52 week high
5.33 usd
52 week low
1.67 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
200.481
Price/Book Value
2.3943
Enterprise Value
144.34M usd
EV/Revenue
169.5614
EV/EBITDA
-23.7838
Key financials
Revenue TTM
1.15M usd
Gross Profit TTM
1.03M usd
EBITDA TTM
-15.62M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
166.67B usd
Net debt
N/A usd
About
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
- Symbol215600.KQ
- ExchangeKQ
- IsinKR7215600008
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Eun-Sang Moon D.D.S., DDS, M.D.
- HeadquarterSeoul
- Web sitehttps://www.sillajen.com
Related news
November 29
JAKOTA Stocks on November 28, 2023 